Table 3 Summary of the outcomes about fiducial markers implantation and tracking concerning the three main tumor localization: lung, prostate and liver
Patients treated with SBRT (n) | Patients treated with fiducial tracking (n, %) | Fiducial markers implanted (n) | Fiducial markers tracked (n) | Technical sucess rate (%) | ⩾ grade 2 toxicities (%) | |
|---|---|---|---|---|---|---|
Lung | 450 | 89 (20%) | 102 | 102 | 100% | 2% |
Prostate | 160 | 150 (94%) | 544 | 470 | 91% | 0% |
Liver | 165 | 151 (92%) | 617 | 461 | 75% | 1% |